Orum Therapeutics

Orum Therapeutics (KRX: 475830) is a public biotechnology company developing TPD2®, a novel class of targeted protein degradation therapeutics. Also known as degrader-antibody conjugates (DACs), these therapeutics combine the precision of antibodies with Orum's novel degrader payloads to break down disease-causing proteins inside specific cells. By enabling the selective degradation of previously “undruggable” targets, Orum is working to improve the effectiveness, safety, and reach of targeted protein degradation. The company’s lead programs target GSPT1, and it is also advancing next-generation payloads to expand the potential of its DAC pipeline. In parallel, Orum is developing proprietary linker technologies to increase the flexibility and precision of future DAC programs. With headquarters in Daejeon, South Korea, and Lexington, Massachusetts, U.S, Orum is globally positioned to deliver first-in-class cancer therapies for patients with hard-to-treat diseases. For more information, visit